Review

Complex interaction of adiponectin-mediated pathways on cancer treatment: a novel therapeutic target

Massimo Monks¹, Foivos Irakleidis², Peng H. Tan²

¹UCL Medical School, Faculty of Medical Science, Royal Free NHS Foundation Hospital, London NW3 2QG, UK.
²Breast Unit, Department of Surgery, Royal Free NHS Foundation Trust, London NW3 2QG, UK.

Correspondence to: Dr. Peng H. Tan, Breast Unit, Department of Surgery, Royal Free NHS Foundation Trust, Pond Street, London NW3 2QG, UK. E-mail: peng.tan@nhs.net


Received: 11 Nov 2018 First Decision: 21 Dec 2018 Revised: 7 Jan 2019 Accepted: 14 Feb 2019 Published: 29 Mar 2019

Science Editor: Umberto Galderisi Copy Editor: Cai-Hong Wang Production Editor: Huan-Liang Wu

Abstract

Obesity has the far reaching consequence on cancer pathogenesis and immune reactions. In particular, adiponectin (APN) produced by adipocytes played an important role in modulating obesity related malignancies. Via its interaction with corresponding receptors and their downstream signalling pathways, it regulates cells survival, apoptosis and cancer metastasis. Our review dissects the clinical evidence on how hypoadiponectinaemia associated with the increased risks of several cancers and the long-term prognosis and also addresses the controversies. APN also has its indirect effect on anti-cancer immune response which may influence the disease process. We also analyse the impact of APN on the immune system, the anti-tumour responses and the controversies surrounding this area. Targeting therapeutics on APN and its receptor axis represents a promising and novel anti-cancer treatment. Biological understanding of how APN and its interaction with its receptors may affect the immune reactivity. Careful strategizing the use of APN therapeutics in cancer treatment is important, as the APN receptor signalling on the immune cells can blunt anti-tumour response. Targeting APN or its receptors has an enormous implication for the treatment of cancers.

Keywords: Adiponectin, AdipoR1/R2, Cancer, signaling pathway, anti-tumor immunity, therapeutic targets

INTRODUCTION

Adipose tissue is no longer seen as only a passive energy store, but instead a complex metabolic and endocrine organ. Composed of adipocytes, nerve tissue, connective tissue matrix, stromo-vascular cells that
can orchestrate the immune cells. It expresses, secretes, and responds to a number of key cellular modulators which may have a prominent role in the development and regulation of the disease process in the body. Adipocytes secrete cell signalling proteins, termed adipokines, of which adiponectin (APN) has been shown to have anti-inflammatory, anti-atherogenic, and anti-diabetic properties.

With obesity being linked to approximately 20% of all cancers, harnessing APN may be of great therapeutic benefit, especially with obesity-related cancer. For this to be successful, it is important to note that adipokines can have both anti-inflammatory and pro-inflammatory properties. When the homeostasis is disrupted, these molecules have the ability to cause harm, yet if we are able to counteract the imbalance, adipokines could pose an important anti-carcinogenic target for the future.

BACKGROUND OF APN AND ITS RECEPTORS

Discovery of APN and its structure

APN was first described in 1995 by Scherer et al. from a cDNA library containing adipocyte-specific genes. Monomeric APN is a 30-kDa glycoprotein encoded by the ADIPOQ gene on human chromosome 3q27. APNs full-length protein (flAcrp) structure was discovered three years later and structurally resembled complement protein C1q and proteins from the tumour necrosis factor (TNF) family. It consists of a N-terminal region, a hyper-variable sequence, a collagen-like fibrous domain linked to a C-terminal C1q-like globular domain [Figure 1]. Similarities between APN and C1q are seen in folding topology, intron positions, and the formation of trimers. Interactions between the collagen-like domains of three monomeric APNs form the low-molecular-weight (LMW) isoform. The LMW isoform then has the ability to form stable multimeric oligomers. Two LMW isoforms can connect via a disulphide bond to form a middle molecular weight (MMW) hexamer. With the help of post-translational modifications larger 12- or 18-mer high molecular weight (HMW) isoforms are generated.

The majority of APN is produced by white adipose tissue, with lower quantities being produced form brown adipose tissue. That said, several studies have demonstrated APN being present much lower concentrations in other tissues: cerebrospinal fluid, cardiomyocytes, skeletal muscle, liver, and bone marrow. The different isoforms are found at varying concentrations throughout the body. The monomeric isoforms

![Figure 1. Structure of APN. Low molecular weight. MMW: middle molecular weight; HMW: heavy molecular weight; flAcrp: full length adiponectin; Acrp: globular adiponectin](image_url)
are confined to adipocytes, the oligomeric isoforms are present in the circulation\textsuperscript{[16]}, and the globular form (gAcrp) trimerise to form a stable complex in the circulation.

These different isoforms are thought to have varying biological effects with the HMW isoform being the most biologically active and having the highest plasma concentration. The normal plasma concentration levels of APN range from 2-30 g/mL\textsuperscript{[17]}. APN levels have been shown to be altered in many disease processes. Coronary heart disease\textsuperscript{[18]}, atherosclerosis\textsuperscript{[18]}, type 2 diabetes\textsuperscript{[19]}, obesity\textsuperscript{[20]}, insulin-resistance\textsuperscript{[20]}, and many cancers are correlated with lower APN levels. Understanding how different isoforms exert effects upon various tissues may be central to understanding the pleiotropic actions of APN within the body.

**APN receptors**

Three receptors are known to bind with APN: AdipoR\textsubscript{1}\textsuperscript{[19]}, AdipoR\textsubscript{2}\textsuperscript{[19]}, and T-cadherin\textsuperscript{[21]}. AdipoR\textsubscript{1} and AdipoR\textsubscript{2} have an internal N-terminal region and an external C-terminal region with a central seven transmembrane domain. The topology of these receptors are extremely similar, sharing 67\% of their protein sequences\textsuperscript{[22]}. However, compared to G-protein coupled receptors, their topology is completely opposite. AdipoR\textsubscript{1} shows high-affinity binding to globular APN, and also binding to full-length APN and is highly expressed in skeletal muscle. While AdipoR\textsubscript{2} shows intermediate-affinity binding to both forms and is predominantly expressed in the liver. More recently, T-cadherin was identified as an additional APN receptor\textsuperscript{[21]}. It is a glycosylphosphatidylinositol-anchored protein that is highly expressed in endothelial and smooth muscle cells, and has shown specific binding to MMW and HMW isoforms\textsuperscript{[23]}.

**APN AND CANCER**

A number of cancers have been correlated with hypoadiponectinemia and altered levels of AdipoR\textsubscript{1}/R\textsubscript{2} and T-cadherin. Therefore, APN may be a novel modifiable risk factor with uses as a prognostic or diagnostic biomarker.

**Colorectal cancer**

It has been long acknowledged that obesity, hyperinsulinaemia, and insulin-resistance are associated with colorectal cancer (CRC) pathogenesis. More recently it has been shown that APN levels are negatively correlated with a risk of developing CRC [Table 1]. This has been confirmed by three meta-analyses\textsuperscript{[24-26]} and multiple studies summarised in Table 1. Not only did CRC patients have lower levels of APN, but one study showed that men with high APN had a 60\% reduced risk of CRC\textsuperscript{[27]}. A following study showed a similar reduced risk in CRC among men, however no link was seen in females\textsuperscript{[28]}. This highlights the point that the expression and response to APN can differ between sexes. APN also seems to have a role at the later stages of CRC and an influence on its clinicopathological characteristics. Two studies showed an inverse correlation between tumour stage/grade and APN\textsuperscript{[29,30]}. Furthermore, low pre-surgical APN levels were found in a higher proportion of relapsing patients, suggesting that APN may have potential to act an adjunctive tool to predict relapse. Mice knock-out models have suggested that interactions with AdipoR\textsubscript{1}, rather than AdipoR\textsubscript{2}, have a more protective role as only AdipoR\textsubscript{1}-KO mice demonstrated increased proliferative activity\textsuperscript{[31]}.

To aid development of any therapy it is important to understand changes that occur to APN within CRC tumour cells. FlAcrp can be post-translationally modified to Acrp within the tumour environment, such that the ratio between flAcrp:Acrp is higher than in the surrounding normal tissue\textsuperscript{[32]}. Local conversion to Acrp could help create a more beneficial tumour environment by functioning in an autocrine manner\textsuperscript{[33]}. Thus, not only do CRC patients often have lower circulating levels of APN, but also a different proportion of APN subtypes that benefit tumour progression.

**Gastric cancer**

APN levels have been shown to have an inverse correlation to gastric cancer (GC) [Table 1]. One study found that GC cells lacking AdipoR\textsubscript{1} had higher peritoneal dissemination and lymphatic metastases than AdipoR\textsubscript{1}
# Table 1. Epidemiological studies showing the relationship of serum APN and cancer

<table>
<thead>
<tr>
<th>Study types</th>
<th>Study outcome</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectal cancer - CRC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCC</td>
<td><em>P</em> &lt; 0.001; <em>P</em> = 0.037</td>
<td>[29]</td>
</tr>
<tr>
<td></td>
<td>1. APN is significantly lower in CRC;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. APN inversely correlates to tumor stage;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Lower APN is associated with CRC recurrence</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>P</em> &lt; 0.05</td>
<td>[67]</td>
</tr>
<tr>
<td></td>
<td>1. Lower APN;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. No correlation visceral fat &amp; APN in CRC or adenoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>P</em> &lt; 0.001 - Lower APN in CRC</td>
<td>[68]</td>
</tr>
<tr>
<td></td>
<td>1. OR = 0.0802 (0.321-1.003) for CRC risk</td>
<td>[69]</td>
</tr>
<tr>
<td></td>
<td>2. OR = 0.442 (0.189-0.946) for adenoma risk - APN is good marker for adenoma</td>
<td>[30]</td>
</tr>
<tr>
<td></td>
<td>OR = 0.72 (0.53-0.99) for CRC risk, <em>P</em> = 0.005 - Lower APN correlates to CRC risk and APN inversely correlates to tumor grade</td>
<td>[71]</td>
</tr>
<tr>
<td>PCC</td>
<td>1. *RR = 0.55 (0.35-0.86), <em>P</em> = 0.02 for men highest vs. lowest quartile</td>
<td>[28]</td>
</tr>
<tr>
<td></td>
<td>2. *RR = 0.96 (0.67-1.39), <em>P</em> = 0.74 for women</td>
<td></td>
</tr>
<tr>
<td></td>
<td>APN significant associated with reduced risk in men but not women</td>
<td></td>
</tr>
<tr>
<td></td>
<td>*RR = (0.23-0.78); P (trend) = 0.01 - Men with low APN had a higher risk of CRC</td>
<td>[27]</td>
</tr>
<tr>
<td></td>
<td>1. *RR = 0.71 (0.53-0.95), <em>P</em> = 0.03 for total APN when comparing highest vs. lowest quintile</td>
<td>[70]</td>
</tr>
<tr>
<td></td>
<td>2. *RR = 0.45, (0.34-0.61), <em>P</em> &lt; 0.0001 for non-HMW APN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total &amp; non-HMW APN inversely correlates to CRC risk</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>P</em> &gt; 0.05; OR = 0.8 (0.5-1.4) for highest vs. lowest APN quartile</td>
<td>[71]</td>
</tr>
<tr>
<td></td>
<td>No significance correction between APN &amp; CRC risk</td>
<td>[72]</td>
</tr>
<tr>
<td></td>
<td><em>P</em> &gt; 0.05 - No significance association</td>
<td></td>
</tr>
<tr>
<td>Gastric Cancer - GC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCC</td>
<td><em>P</em> = 0.0004 - APN levels were significantly lower in Stage I cases than controls</td>
<td>[73]</td>
</tr>
<tr>
<td></td>
<td><em>P</em> &lt; 0.05 - Negative correlation with pathologic findings such as tumor size, depth of invasion, tumor stage (only in undifferentiated GC)</td>
<td>[74]</td>
</tr>
<tr>
<td>RCC</td>
<td><em>P</em> &gt; 0.05 - No significant difference in tumor stage, localization, nodal status, lymphatic and vascular invasion</td>
<td>[75]</td>
</tr>
<tr>
<td>Oesophageal Cancer - OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCC</td>
<td><em>P</em> &lt; 0.05; <em>P</em> &lt; 0.05 - Significantly lower APN levels in ESCC &amp; EA patients than controls</td>
<td>[76]</td>
</tr>
<tr>
<td></td>
<td>EA patients had lowered APN than ESCC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>*HR = 0.34 (0.14-0.82) - Nonlinear inverse association with risk of EA; the strongest associations were observed in 2nd tertile</td>
<td>[77]</td>
</tr>
<tr>
<td></td>
<td><em>P</em> = 0.01 - Serum APN was significantly lower in cases than controls</td>
<td>[78]</td>
</tr>
<tr>
<td></td>
<td><em>P</em> = 0.802 - APN levels were similar in various esophageal pathologies</td>
<td>[79]</td>
</tr>
<tr>
<td>Breast Cancer - BC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCC</td>
<td>1. Adjusted OR = 0.2 (0.0-0.6); <em>P</em> &lt; 0.05; 80% reduced risk in higher APN compared with stage I-II [40,41,80]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Adjusted OR = 0.04 (0.071-0.99) - Lower APN in early breast cancer vs. healthy controls [46]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. <em>P</em> = 0.04 - 65% reduced risk in higher APN compared with stage I-II [40,41,80]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. <em>P</em> &lt; 0.005 (for tumor size); <em>P</em> &lt; 0.05 (for grade); &gt; 2 cm tumor &amp; Grade 2&amp;3 BC cases were higher in lower tertile of serum APN [42,43]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. <em>P</em> = 0.036 - Negative correlation with tumor size [42,43]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>*P (trend) = 0.0270 - Inverse trend in ER/PR -ve BC (for not +ve)</td>
<td>[44]</td>
</tr>
<tr>
<td></td>
<td>Adjusted HR = 0.39 (0.15-0.95) - Higher APN was associated longer BC (stage I-IIIA) survival</td>
<td>[81]</td>
</tr>
<tr>
<td></td>
<td>Adjusted HR = 0.88 (0.81-0.96); <em>P</em> = 0.03; Lower APN was associated with a history of prior pT1mic/pT1a &amp; higher risk of second BC in premenopausal and 12% reduction in risk of BC per unit increase of APN</td>
<td>[82]</td>
</tr>
<tr>
<td></td>
<td>1. <em>P</em> = 0.017 [83]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. OR = 0.805 (0.704-0.921); <em>P</em> = 0.00 [83,84]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lower APN was associated with nodal disease [83,84]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Post-menopausal OR = 0.73 (0.55-0.98) but pre-menopausal OR = 1.30 (0.80-2.10) (all women OR = 0.89 (0.71-1.1))</td>
<td>[85]</td>
</tr>
<tr>
<td></td>
<td>Negative correlation in post-menopausal women</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>P</em> = 0.43 for linear trend - No association with risk</td>
<td>[45]</td>
</tr>
<tr>
<td>Endometrial Cancer - EC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCC</td>
<td>*OR = 0.56 (0.36-0.86) highest vs. lowest APN quartile</td>
<td>[86]</td>
</tr>
<tr>
<td></td>
<td>Negative correlation independent of other obesity-related risk factors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>OR = 0.42 (0.19-0.94) comparing highest vs. lowest tertile</td>
<td>[48]</td>
</tr>
<tr>
<td></td>
<td>Inverse association with risk of EC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stronger association in pre-menopausal than post-menopausal</td>
<td></td>
</tr>
<tr>
<td>RCC</td>
<td>*OR = 0.52 (0.32-0.83); <em>P</em> &lt; 0.001 - Significant negative correlation between APN level and EC risk</td>
<td>[87]</td>
</tr>
<tr>
<td></td>
<td><em>P</em> &lt; 0.001; <em>P</em> &lt; 0.05 - Significantly lower APN in EC patients than normal or polyps epithelium patients</td>
<td>[88]</td>
</tr>
<tr>
<td></td>
<td><em>P</em> &lt; 0.0001 - Significantly reduced APN in cases than controls; Leptin-APN ratio correlated to post-menopausal EC risk</td>
<td>[89]</td>
</tr>
</tbody>
</table>
positive cells\textsuperscript{[34]}. Despite, the AdipoR1 positive group having longer survival rates, multivariate analysis indicated this was not an independent prognostic factor on GC survival. That said, it is thought AdipoR1 is the mediator of tumour growth suppression in GC and therefore could be a therapeutic target in tackling GC. One study demonstrated that rs266729, an ADIPOQ variant, may be an independent prognostic factor for non-drinking GC patients receiving surgical treatment\textsuperscript{[35]}. Similarly, APN levels have been shown to have a direct effect in GC postoperative outcomes. It was shown that the ratio of postoperative to preoperative levels of APN was the most useful predictor for postoperative infection\textsuperscript{[36]}. It is thought that reduced APN levels suggest a submaximal inflammatory response, thus predisposing to infection\textsuperscript{[32]}. Increasing APN in the weeks before surgery could be an additional method to improve surgical outcomes.

### Oesophageal cancer

APN plays a significant role in the maintenance of the normal oesophageal mucosa\textsuperscript{[32]}. Lower levels of APN have been correlated with an increased risk of oesophageal cancer (OC) [Table 1]. Low tumour expression of AdipoR1 was suggested to be an independent predictor of improved overall OC survival\textsuperscript{[27]}. While, AdipoR2...
expression was inversely correlated with tumour size. It was shown that low levels of LMW and high levels of HMW APN compared to the total APN ratio increased the risk of Barrett’s oesophagus, which contributes to OC propagation[38]. Looking at the dynamic changes between LMW and HMW APN levels during OC transformation could present an interesting predictive biomarker.

**Breast cancer**
A recent meta-analysis confirmed a link between hypoadiponectinaemia and an increased breast cancer (BC) risk[39]. This increased risk was only found in post-menopausal women and not pre-menopausal women. Risk reduction in early BC patients with high APN levels has been reported to be from 65%-80%[40,41]. A negative correlation has been demonstrated between APN levels and tumour size and grade[42,43]. Interestingly, the correlation between APN and BC seems to be more prominent in oestrogen-negative and progesterone-negative BC[44]. Therefore, it seems there may be a set group of BC patients that are most susceptible to the effects of APN and would benefit most from a potential treatment. That said, certain studies have shown no correlation between APN and BC risk[45].

**Endometrial cancer**
A significant negative correlation has been found between levels of APN and endometrial cancer (EC)[46][Table 1]. A meta-analysis found that high levels of APN reduced the risk of EC by 53%[47]. Whether APN levels effect pre- or post-menopausal women is unclear as studies have produced varying results[47-49]. One proposed protective mechanism of action is that APN can reduce the number of EC cells by inhibiting proliferation and stimulating apoptosis[49,50]. One study looked into the serum levels of the APNs isoforms and found that low levels of MMW isoform were the only independent risk factor for EC[51]. It is unclear why this isoform in particular was most closely associated with EC, but highlights the pleiotropic effects APN exerts through its multiple isoforms.

**Pancreatic cancer**
The association between APN levels and pancreatic cancer (PC) is unclear from current studies [Table 1]. Some studies demonstrated a negative correlation between serum APN and PC[52], while others showed high APN levels increasing the risk of PC[53]. Of note, high APN levels were associated with a reduced PC risk in people that never smoked, but no significance found in smoker[54]. PC has significant mortality associated with its diagnosis with a 5-year survival of only 9%[55], therefore early detection using biomarkers could significantly alter treatment and prognosis. However, further prospective studies are needed to confirm APN as a PC marker.

**Renal cancer**
A negative correlation has been shown between serum APN and renal cancer (RCC), tumour stage, and metastasis[56-58]. That said, one study showed how APN may exert different effects depending on ethnicity as a positive correlation was found between APN and RCC in African Americans but not Caucasians[59].

**Prostate cancer**
A negative correlation between APN levels and prostate cancer (PrC) tumour grade and stage has been demonstrated in several studies [Table 1]. One study showed that the reduced risk was only found in obese and overweight men, but not all men[60]. Furthermore, four ADIPOQ single nucleotide polymorphisms (SNP) (rs266729, rs182052, rs822391 and rs2082940) were shown to be significantly associated with PrC risk in Caucasians[61]. Once again highlighting the differing effects of APN in different ethnicities.

**Hepatic cancer**
The relationship between hepatic cancer (HC) and APN levels is unclear [Table 1]. Certain studies showed that higher APN levels predicted a poorer survival with HC[62]. APN expression pairs with tumour size but not several other parameters, therefore the rise in APN with tumour tissue may occur throughout the
process of carcinogenesis in an attempt to counteract the change and restore\(^{[32]}\). Others studies suggested poor HC prognosis was associated with lower AdipoR1/R2 expression\(^{[63]}\). AdipoR1 expression was correlated with the absence of vascular invasion and AdipoR2 was associated with a low stage and a lower histological grade. Although the role of APN in HC is unclear, APN may have a role pre-malignant hepatic conditions such as non-alcoholic steatohepatitis (NASH)\(^{[32]}\). APN can suppress the hepatic damage caused by TNF-\(\alpha\) in early NASH, thus highlighting an area where targeted APN treatment could help halt progression to cirrhosis and cancer.

**Lung cancer**

The majority of studies have not found a significant correlation between APN levels and lung cancer (LC) \([Table 1]\). Yet, one study demonstrated that there were lower levels of APN were present in patients with advanced disease compared to limited stage disease\(^{[64]}\). AdipoR1 and AdipoR2 were only expressed in the cancerous tissue, with non-found in normal control tissue. Further studies are needed to determine a link between APN and LC.

**Genetic polymorphisms**

Multiple genetic polymorphisms have been associated with altered risk of malignancy in ADIPOQ, ADIPOR1, and ADIPOR2\(^{[65]}\). These SNPs have been associated with a wide number of cancers and may enable screening and identification of high risk patients. This can allow for primary preventive measures, such as losing weight, diet, and exercise, as well as chemoprevention\(^{[66]}\). Going forward we need to be take into consideration the interaction between various SNPs, ensure that a large and diverse group of the population are screened for more SNPs, and determine how SNPs can be applied to clinical decision making.

**DIRECT EFFECT OF APN PATHWAY ON CANCER BIOLOGY**

Insulin resistance and hypoadiponectinemia have been associated with multiple cancers. The binding of APN to AdipoR1/R2 triggers a number of downstream signalling cascades which have effects on cancer biology and anti-cancer immunity. Understanding these pathways can help give light to the multitude of APNs metabolic and immunological effects. These pathways are summarised in Figure 2.

Central to much of APNs actions is the AMP-activated protein kinase (AMPK) pathway\(^{[102,103]}\). AMPK can act as a tumour suppressor by modulating inflammation, inducing cell-cycle arrest, and opposing metabolic changes during carcinogenesis\(^{[104]}\). AMPK activation has been shown to have a beneficial effect on insulin sensitivity by increasing glucose uptake and fatty acid oxidation in muscles, and inhibiting gluconeogenesis in the liver. Interestingly, disruption of AdipoR1 reduced the AMPK activation, increased glucose production and impaired insulin resistance. While, AdipoR2 disruption enhanced insulin resistance and decreased PPAR\(\alpha\) signalling\(^{[20]}\). Downstream inhibition of the mTOR pathway contributes to AMPKs tumour suppressive qualities\(^{[105,106]}\). This is due to mTORs central role as a regulator of cell growth, autophagy, and cell survival\(^{[107]}\). AMPK activation has also been shown to be cytotoxic to cancer cell lines and cause apoptosis via p21 and p53 signalling\(^{[108]}\). AMPK has the ability to monitor and respond to cellular energy requirements. In times of hypoxia, nutrient starvation, and redox imbalance, liver kinase B1 (LKB1) - its upstream kinase - activates AMPK. The importance of LKB1 can be seen in patients with Peutz-Jegher syndrome who are heterozygous for a LKB1 gene mutation. Development of a second mutation in life then greatly increases the risk of multiple cancers. It is hypothesised that the loss of AMPK activation may contribute to this development of malignancy\(^{[109]}\). LC and HC patients have shown evidence of LKB1 mutations and low LKB1 expression respectively\(^{[106]}\). Therefore, APN mediated AMPK activation could help prognosis and disease progression in these specific cancers.

The PI3K/AKT pathway promotes cellular survival, growth, and proliferation\(^{[110]}\). This signalling pathway is specifically known to be involved in gastrointestinal cancers (GI) whereby upstream mutations lead to
Several factors related to obesity have been shown to induce this pathway and potentially result in carcinogenesis, thus making it a good target for obesity related GI cancer. APN can directly\cite{111} and indirectly\cite{112} inhibit the PI3K/AKT signalling pathway.

APN also interacts with several other pathways that are involved in carcinogenesis and the maintenance of tumour survival including: the Wnt/GSK3β/B-catenin-signalling pathway\cite{113}, signal transducer and activator of transcription-3 (STAT-3), and mitogen activated protein kinase (MAPK). APN inhibits STAT-3 which has a role in cancer cell proliferation, invasion, and survival\cite{114}. STAT-3 promotes pro-oncogenic inflammatory pathways, including NF-κB and IL-6-Janus tyrosine kinase, and inhibits the STAT-1 and NF-κB mediated T helper 1 anti-tumour immune response\cite{114}. Both gAcrp and fAcrp have the ability to suppress STAT-3 and the associated JNK pathways in HC and PrC\cite{115}. APN also interacts with the MAPK which signals through cJNK, MAPKp38, and extracellular signal-regulated kinases (ERK)1/2\cite{40,116,117}.

Multiple studies have found that AdipoR1/R2 are over-expressed in cancers. In the setting of hypoadiponectinemia it makes sense to have a compensatory upregulation of the receptors. However, this seems counter-intuitive as the cancer cells are over-expressing receptors that act to hinder their growth and proliferation. It is suggested that in a metabolically deprived tumour environment the cells metabolic needs take priority\cite{17}. That said, it has been shown that APN can also have proliferative effects on cancer cells\cite{118}. Further studies looking into how the expression of APNs receptors changes throughout tumorigenesis are important as the biological effects of APN depend on the tissue-specific expression of these receptor subtypes\cite{32}.
One of the mechanisms by which APN prevents cancer growth is by promoting apoptosis via cytotoxic autophagy. A recent study using BC cells demonstrated that APN induces an accumulation and fusion of autophagosomes and lysosomes which leads to apoptosis. Central to this pathway is the AMPK mediated activation of the ULK1 (Unc-51 like autophagy activating kinase 1) axis which is regulated by upstream STK11/LKB1 (serine/threonine kinase 11/Liver kinase B1) \[^{119}\]. Autophagy can be cytoprotective, cytotoxic, cytostatic, or non-protective. Due to the cytoprotective role of autophagy many studies have looked to see whether inhibition of autophagy can be used in combination with chemotherapy to increase sensitivity to therapy \[^{120}\]. In contrast, this study has shown that by stimulating cytotoxic-autophagy it can enhance efficacy of chemotherapy. The dual role of autophagy in tumour suppression and promotion makes utilising this pathway therapeutically challenging and more studies are needed to determine how APN induced autophagy can be used in combination with other treatments.

The intracellular accumulation of ceramides have been associated with pathogenesis such as insulin resistance and endothelial dysfunction \[^{121,122}\]. Activation of ceramidase enhances ceramide catabolism to the anti-apoptotic sphingosine-1-phosphate \[^{123}\]. A recent study showed that APN signalling through T-cadherin, but not AdipoR1/R2, reduced cellular ceramide by enhancing exosome biogenesis and secretion \[^{124}\]. This is a novel mechanism by which APN can lower intracellular ceramide and prevent cellular damage. Unlike AdipoR1/R2, T-cadherin is usually downregulated in cancer cells and re-expression of the receptor has been associated with a better prognosis \[^{120}\]. Despite APNs anti-oncogenic pathways, dominance of the ceramidase pathway may enable over expression of AdipoR1/R2 to be pro- rather than anti-oncogenic. When assessing the overall effect of APN, it is important to consider the time at which AdipoR1/R2 are overexpressed in cancer, the concentration of serum APN, and which isoform is circulating.

INDIRECT EFFECT OF APN PATHWAY ON ANTI-CANCER IMMUNITY

Chronic inflammation in adipose tissue, mediated by adipokine signalling, and immune system dysfunction hold important roles in cancer initiation \[^{126}\]. APN has been shown to have anti-inflammatory properties through interaction with the innate and adaptive immune system \[Table 2\]. The majority of this is mediated by antigen-presenting cells (APC) of the innate immune system that produce anti-inflammatory cytokines and inhibit pro-inflammatory cytokines. That said, APN has also been shown to have pro-inflammatory effects \[Table 2\], suggesting that there may be situations where APNs effects shift from anti- to pro-inflammatory.

One of the central anti-inflammatory cytokines APN induces is IL-10 \[Table 2\]. The mechanism of IL-10 transcription from APN may be mediated through several pathways. One known pathway is that gAcrp exposure leads to AMPK and ERK1/2 mediated CREB transcription of IL-10 \[^{128}\]. Multiple studies have demonstrated that gAcrp is the best inducer of IL-10. However, one study showed that activation of AdipoR1 by either gAcrp or flAcrp can upregulate IL-10 through the AMPK and MAPKp38 pathway \[Figure 3\]. IL-10 has a multitude of anti-inflammatory effects \[^{164}\], one of these may be exerted through activation of the STAT3/ suppressor of cytokine signalling (SOC3) pathway. Activation of the IL-10 receptor activates this pathway which leads to downstream inhibition of NF-κB \[Figure 3\].

Although APN levels are generally negatively correlated with cancer risk, high expression of the APN receptors has equally been correlated with tumour progression. Activation of upregulated AdipoR1 and AdipoR2 on dendritic cells (DC) results in the arrest of DCs in an immature state and development of tolerance to tumour antigens \[^{147}\]. Each APN receptor has a separate pathway leading to inhibition of the NF-κB pathway thought to induce DC tolerance \[Figure 3\]. That said, suppression of the NF-κB pathway is a central anti-inflammatory mechanism that APN utilises \[Table 3\]. Activation of AdipoR1 results in a IL-10 dependent activation of the STAT3/SOC3 pathway and inhibition of the NF-κB pathway. A STAT3-knockout-DC study demonstrated that STAT3 is essential in developing the IL-10 dependent tolerance \[^{160}\].
Table 2. Effect of APN on the immune system

<table>
<thead>
<tr>
<th>Anti-inflammatory effects</th>
<th>Macrophages</th>
<th>Monocytes</th>
<th>Natural killer cells</th>
<th>Regulatory T cells</th>
<th>T cells</th>
<th>B cells</th>
<th>Liver cells</th>
<th>Fibroblasts</th>
<th>Pro-inflammatory effects</th>
<th>Dendritic cells</th>
<th>Macrohages</th>
<th>Endothelial cells</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Inducing anti-inflammatory cytokine; IL-10[132], IL-1RA[132]</td>
<td>1. Inducing anti-inflammatory cytokines; IL-10[127-129], IL-1RA[127]</td>
<td>1. Inhibiting adhesion molecule, ICAM-1 (CD54)[131], E-selectin[132], αVEGFR[132]</td>
<td>1. Inducing expansion of Treg[137]</td>
<td>1. Activating T cells via induction of INF-α[134], IL-6[134,135], TNF-α[134], IFN-γ[134], I-TAC/CXCL11[141], Mig/CXCL9[141], CCL18[141]</td>
<td>Inhibiting B lymphopoiesis[137]</td>
<td>1. Inducing anti-inflammatory cytokine, IL-10[127]</td>
<td>Only inducing transient TNF-α[138]</td>
<td>1. Promoting positive co-stimulators; CD86[139], CD40[139]</td>
<td>2. Up-regulating HLA II[139]</td>
<td>3. Inhibiting positive co-stimulator (CD80[140])&lt;sup&gt;*(APN suboptimal)&lt;/sup&gt;</td>
<td>1. Inhibiting adhesion molecule, ICAM-1 (CD54)[131], E-selectin[132], αVEGFR[132]</td>
</tr>
</tbody>
</table>

This table summarizes the controversies surrounding the role of APN on the immune system. On balance, majorities of work support the role of APN regulating the immune system negatively. However, the caveats associated with the ability of APN to stimulating the immune system are also demonstrated (as per discussed in the text). The body of evidence on this area tends pale into insignificance comparing to the large experimental data supporting the notion of APN as an immune modulator. IRS-2: insulin receptor substrate-2; ROS: radical oxygen species; C/EBPa: CCAAT/enhancer binding protein-alpha; MCP-1: monocyte chemoattractant protein-1; EPC: endothelial progenitor cell; eNOS: endothelial nitric oxide synthase; IP-10: interferon (IFN)-inducible protein-10; I-TAC: IFN-inducible T cell alpha chemoattractant; Mig: monokine induced by IFNγ, M1 markers (TNF-α, IL-6, MCP-1), CRT/CD91; CRT: calrecticulin; HO-1: heme oxygenase-1; TF: tissue factor; Treg: regulatory T cells

Despite STAT3 being recognised as the dominant mediator for IL-10 functions, this pathway can mediate anti-inflammatory effects in an IL-10 independent manner[148]. This includes downstream activation of ETS family transcriptional repressor, ETV3 and a helicase family corepressor, Strawberry notch homologue 2 (SBN02) that can inhibit NF-κB activation[147].
The second distinct tolerogenic pathway is activated through AdipoR2 [Figure 3]. In AdipoR1-depleted DCs, use of IL-10 receptor antibodies had no effect on the DCs ability to induce T-cell tolerance - suggesting this is a IL-10 independent tolerance process. Instead, the COX-2 pathway upregulates peroxisome proliferator-activated receptors-γ (PPARγ), inhibiting the NF-κB pathway, and promoting anergic phenotypes on engaging T cells\[^{117}\]. After DCs interact with allogenic T cells the PPARγ pathway drives Th2-cytokine production. Treating DCs with PPARγ agonists produced similar responses\[^{176}\]. DCs with a more dominant AdipoR2 signalling produced significantly more Th2-skewing cytokine production than AdipoR1-dominant DCs\[^{177}\]. It is thought that the SOCS3 pathway may cause the smaller AdipoR1-dependent Th2-cytokine production\[^{177}\]. The role of PPARγ is further confirmed through a PPARγ-knockout model that prevented tolerance developing\[^{117}\]. It was thought that downstream NF-κB effectors may contribute towards T-cell tolerance. However, inhibiting anti-NF-κB effectors was unable to prevent DC promotion of T-cell anergy\[^{117}\]. These studies demonstrate AdipoR1/R2 pathways that enable DC-tolerance and allow cancer evade the immune system.

The role of T-cadherin and APN on the immune system is less known. One proposed mechanism is immune modulation through the enhancement of exosome biogenesis and secretion\[^{124}\]. When exomes are released from a cell, this may protect cells by modulating the immune function of recipient cells\[^{178}\], or stimulating repair of neighbouring cells\[^{179}\].

One study showed that T-cadherin is upregulated on chronic cold exposure, enabling APN to be recruited to M2 macrophage cell surface, and promote macrophage proliferation\[^{180}\]. Activation of browning and thermogenesis via this pathway may be a further mechanism that APN uses to protect from metabolic stress. Interestingly, in an AdipoR1 and AdipoR2 depleted system, APN-induced T-cell anergy was reversed, suggesting that T-cadherin mediated APN signalling is unlikely to contribute to this process\[^{117}\].
APN has the ability to polarise macrophages towards a M2 anti-inflammatory rather than a M1 pro-inflammatory phenotype [Figure 4]. The administration of APN stimulated expression of M2 markers and reduced expression of M1 markers in human macrophages and adipose tissue [168]. APN mediated macrophage polarisation is thought to occur in a IL-10 dependent manner [131,135,138,158,159,162,169]. The gAcrp and fAcrp polarise macrophages by using separate signalling pathways. The gAcrp stimulates CREB that results in an IL-10 mediated M2 polarisation [128]. Whereas, fAcrp utilizes a IL-4/STAT6-dependent mechanism [142]. One study demonstrated that fAcrp, through AdipoR2, greatly polarised macrophages to an M2 phenotype. Whereas, gAcrp signalling via the AdipoR2, was much less effective at polarising to the M2 phenotype [142].

There is significant evidence showing that APN can suppress pro-inflammatory cytokines including TNF-α, IL-1β, IL-6 [Table 2]. Multiple studies have linked APNs anti-inflammatory effects to TNF-α suppression.
APN-knockout mice showed high levels of TNF-α in both plasma and adipose tissue\(^5\). APN also inhibits a TNF-α induced adhesion molecule\(^5\) which was found to be in high expression in APN-knockout mice\(^5\). Using a reperfusion model, administration of APN reduced apoptosis and TNF-α expression via AMPK and COX-2 respectively\(^5\). However, certain studies have shown that APN causes a rise in TNF-α\(^5\).

The initial increase in TNF-α is mediated by the ERK1/2 pathway which activates early-growth response protein-1 and via a NF-κB-dependent pathway. Despite an initial rise in TNF-α, it leads to an increased expression of IL-10, eventually shifting the system from a pro- to anti-inflammatory state\(^5\).

Other studies have identified further pro-inflammatory effects of APN [Table 2]. One study demonstrated that through an unidentified APN receptor, APN increased IL-6 production through NF-κB activation\(^1\). APN was again shown to activate the NF-κB pathway via phospholipase C (PLC)-γ and the c-Jun N-terminal Kinase (JNK) pathway\(^1\). This lead to DC activation and enhanced Th1 and Th17 responses. In adult rat cardiac fibroblasts, gAcrp activation of AdipoR1 induced IL-6 synthesis and release through AMPK, p38MAPK, and ERK1/2 pathways\(^1\). However, through AdipoR1 signalling, A20 (zinc finger protein) and B-cell lymphoma 3-encoded protein (Bcl3) upregulation can counter-inhibit IL-6 signalling induced by APN\(^1\). This complicates the overall picture of APN as an anti-inflammatory cytokine, but likely reflects the complex homeostatic mechanisms that are occurring. Although some evidence suggests APNs pro-inflammatory nature, the overwhelming evidence across a number of cell lines suggest to the contrary [Table 2].

An important consideration in whether APN exerts pro- or anti-inflammatory properties is the concentration that is used in studies. The physiological level of APN in a non-obese, non-diabetic patient is \(~10\) µg/mL\(^1\). When conditioning immune cells, we must take into consideration the concentration of APN used. In certain systems, when the conditioning of immune cells was done at physiological levels, the
opposite effect occurred\textsuperscript{186}. Therefore, the concentration of APN used for conditioning may greatly change the outcome of a study.

Many of the studies showing APN having pro-inflammatory effects used concentrations of \~10 µg/mL\textsuperscript{160,186}. A recent study demonstrated that approximately a plasma APN concentration of 40 µg/mL was needed to induce IL-10 production and an anti-inflammatory response\textsuperscript{187}. Furthermore, physical exercise can increase APN by 260% off baseline\textsuperscript{189}. Therefore, it may be unlikely that using a physiological level of APN would result in the desired anti-inflammatory effects due to sub-optimal signalling.

Interpreting APNs role on immune cells is further complicated as the kinetics of AdipoR1/R2 differ depending on the specific immune cell and stage of differentiation. Expression of AdipoR1/R2 occurs in 80%-90% of CD14\textsuperscript{+}, compared to 10% of T-cells\textsuperscript{156}. As monocytes differentiate into macrophages AdipoR1 expression decreases, whereas AdipoR2 expression is constant\textsuperscript{190}. Likewise, the presence of various APN oligomers and the multitude of signalling differences make it hard to pinpoint APNs exact role. For example, differences are observed between HMW APN and gAcrp inhibition of the NF-κB pathway\textsuperscript{191}. HMW APN required shorter incubation period to inhibit NF-κB compared with gAcrp. While gAcrp produces a transient activation and requires a longer incubation period to inhibit the pathway\textsuperscript{191}.

In the adaptive immune system APN has been shown to act as a negative regulator for T-cells\textsuperscript{156} and affect the migration of T-cells towards diseased tissue\textsuperscript{141,149}. Although only 10% of T-cells express AdipoR1/R2 on their surface, the majority of T-cells store these receptors within intracellular clathrin-coated vesicles. After stimulation, T-cells upregulate these receptors on the surface and APN interaction subsequently enhances apoptosis and inhibits proliferation. In APN-deficient mice, infection lead to a significantly higher number of CD137\textsuperscript{+} T-cells\textsuperscript{136}. Furthermore, culturing APN-DCs with allogenic T-cells decreased T-cell proliferation and pro-inflammatory cytokine production\textsuperscript{146}. A rise in regulatory T-cells was also identified, providing an alternative mechanism that APN can regulate the immune system\textsuperscript{146}. With regard to migration, APN can inhibit expression of chemokines that act as T-cell chemoattractants in atherogenesis\textsuperscript{144}. Therefore, when APN levels are low in cancer, this could favour T-cell recruitment, and contribute towards adaptive immune response. Lastly, one study suggested that rather than affecting proliferation, APN directly activates CD4\textsuperscript{+} T-cells and increases secretion of interferon-γ and IL-6\textsuperscript{160}. It is thought that this inflammatory activation likely desensitises the cells to further pro-inflammatory stimuli. That said, this study uses a low concentration of APN which may influence our interpretation of the results.

**FUTURE IMPLICATIONS OF INTERFERING WITH THE APN PATHWAY ON CANCER TREATMENT**

It is clear that APN has the ability to alter cancer outcomes, biology, and anti-cancer immunity. Therefore, APN has been identified as a therapeutic and preventive target for cancer therapy. The pleiotropic nature of various APN isoforms has caused trouble initially engineering an APN analogue, consequently groups decided to screen for endogenous agonists or enhancing existing APN levels.

The first APN receptor agonist screened for and produced was ADP355\textsuperscript{192}. ADP355 binds both AdipoR1/R2, with a greater affinity to AdipoR1\textsuperscript{192}. In vivo, this agonist inhibited orthotopic human BC xenograft growth by 31%, with an acceptable safety profile. Similar to gAcrp, ADP355 regulated signalling pathways AMPK, STAT3, PIK3/Akt, and ERK1/2. The group was able to improve agonistic activity by 5-10 fold by substituting Gly4 and Tyr7 residues with Pro and Hyp respectively\textsuperscript{193}. High-throughput screening identified several endogenous adiponectin ligands: AdipoR1 agonists included matairesinol, arctiin, (-)-arctigenin and gramine, while AdipoR2 agonists included parthenolide, taxifoliol, deoxyschizandrin, and syringing\textsuperscript{194}. Further studies identified AdipoRon as a strong AdipoR1/R2 agonist at low micromolar concentrations, signalling through AMPK and PPAR-\textgreek{a} pathways\textsuperscript{195}. 
An alternative proposed method is to augment endogenous APN levels using PPARγ ligands. Using synthetic PPARγ ligands, one group demonstrated that expression and secretion of APN increased in a dose and time dependent manner. Efataztazone, a selective PPARγ agonist, showed promise on a phase I trial in metastatic solid tumours, metastatic colorectal cancer, and thyroid cancer patients. However, trials were terminated after phase 2 due to insufficient efficacy.

Another PPARγ agonist Troglitazone has gained much attention in recent years. Troglitazone has been shown to inhibit migration and invasion in human prostate cancer cells, inhibit matrix metalloproteinase-9 expression and invasion of breast cancer cells, and have anti-tumour effects without marked adverse effects. One study showed that Troglitazone mediated PPARγ activation enhances human lung cell cancer cells to TRIAL-induced apoptosis. Suggesting that if used in combination with TRIAL protein it could be useful against TRIAL-resistant cancer cells. That said, phase II studies in refractory breast cancer and metastatic colorectal cancer have had disappointing results. A synthetic derivative of Troglitazone, Δ2-Troglitazone was shown to be more potent in reducing cancer cell proliferation, however no clinical value has been found.

Rosiglitazone, a PPARγ agonist, has been shown to have beneficial effects on atherosclerosis, insulin resistance, and type 2 diabetes. However, a phase II trial using Rosiglitazone in liposarcoma patients concluded that this agonist was not an effective anti-tumour drug. It is important to highlight the side-effect profile of these trial drugs. Rosiglitazone has been shown to increase risk of cardiovascular disease and Troglitazone presents concerns regarding hepatotoxicity. Additional cautions should be taken with chronically elevated APN levels which can be linked to infertility and reduced bone density.

Furthermore, interfering with the AdipoR1/R2 pathways can have adverse effects for anti-tumour immune response, consequently a fine balance must be achieved to ensure the anti-cancer pathways are promoted.

With there being limited success with current therapeutic agents one current use for APN is as prognostic markers for cancer. Both serum APN levels, the expression of AdipoR1/R2, and SNPs could all provide avenues for prognostic and predictive molecular tests in cancer. A number of SNPs in ADIPOQ or APNs receptors have been found associated with BC, CRC, EC, GC, PC, HC, RCC, PrC, and LC. The question arises whether there would be any change in clinical decision making through screening these SNPs or whether they would give any benefit above currently used biomarkers. That said, if well targeted, these tests could help early diagnosis, aid post-operative recovery, and initiate APN modulatory therapy.

It has been shown that a Mediterranean-type diet, reduction in body weight, and exercise can increase circulating APN levels. Furthermore, aerobic exercise was shown to increase expression of AdipoR1 and AdipoR2 in young men. Therefore, using programmes that promote weight loss and a healthy diet in parallel with new APN promoting agents may enable more favourable outcome. Similarly, new APN therapeutic agents may show more promise when being used in combination with traditional treatment by sensitising cancer cells.

A number of cancers are strongly associated with chronic inflammatory processes, for example the association between inflammatory bowel disease and CRC, or Helicobacter pylori infection and GC. These type of cancers could greatly benefit from the anti-inflammatory properties of APN. In cancer there is often defective inflammatory responses, the goal is to restore the normal overall host response, without undesirable side effects. However, one needs to acknowledge that by altering these metabolic pathways there is a chance of detrimental changes to anti-tumour immunity. Moreover, as carcinogenesis progresses, there are changes to the way the tumour environment harnesses the immune system, therefore the timing of treatment may greatly alter the efficacy.

When considering APN as a therapeutic agent it is important to highlight several points. Firstly, many factors influence the levels of circulating APN. Sex, age, ethnicity, and intra-abdominal fat all have
independent roles in determining APN levels\textsuperscript{[219]}. This is important to consider as a therapeutic agent may have greatly differing effects across individuals. Secondly, the pleomorphic nature of APNs isoforms mean it will be hard to replicate each isoforms action. One option would be to use recombinant APN, however this has been difficult to produce and would be expensive over the long term. The solution has been to attempt to increase endogenous APN, but we must consider whether it may be beneficial to selectively increase one isoform. Thirdly, the dosage APN used can affect the inflammatory response in a varied manner. In creating a novel agent, the dose regime must be carefully designed to ensure the desired response is seen.

CONCLUSION

Obesity related-cancers are now a recognised phenomenon. APN is the key adipokine produced by the fat cells and its role in cancer pathogenesis and disease prognosis is now slowly revealed. Hypoadiponectinaemia is often found to be associated with cancers and also affects their prognosis. Therefore, various efforts have been made to harness its therapeutic effects. It can be applied either therapeutically or prophylactically to treat various cancers. For example, identification of ADIPOQ, AdipoR1 and AdipoR2 SNPs that may confer altered risks of cancer development may enable early screening and APN level augmentation via therapeutic interventions.

Overall this field holds a huge promise, however many challenges will need to be addressed prior to its routine use. Cellular and molecular function of APN in cancer either its pathogenesis phase or advanced forms of cancer will need to be fully researched. APN may have different effect on various stages of cancers either directly or indirectly via immune system. The role of each isoform in distinct tissues and under specific conditions needs be clarified. More importantly, the molecular conditions under which APN acts as cancer suppressing or promoting and anti-inflammatory or pro-inflammatory still needs to be fully evaluated. The exact roles of APN interacting which receptors (some identified but some remained to be defined) and their downstream pathways in different cancer have largely remained elusive. Exploring an effective APN-based therapeutic and when to applied this therapeutic may be the crucial step. Understanding the complexity of APN on anti-tumour response may need to be considered when using it as a therapeutic agent.

DECLARATIONS

Acknowledgments
Due to the space restrictions, the authors were able to cite only a fraction of the relevant literature. We apologize to any colleagues whose contribution might not be appropriately acknowledged in this review.

Authors’ contributions
Wrote and prepared most of the manuscript: Monks M
Contributed toward the revision of manuscript: Irakleidis F
Provided guidance and mentorship to all authors in writing and revising the manuscript: Tan PH

Availability of data and materials
Not applicable.

Financial support and sponsorship
Tan PH is funded by Royal Free NHS Foundation Trust as a full-time Consultant Oncoplastic Breast Surgeon.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.
REFERENCES


72. Wang SN, Yang SF, Tsai HH, Lee KT, Yeh YT. Increased adiponectin associated with poor survival in hepatocellular carcinoma. J


